Abiomed (ABMD) Tops Q1 EPS by 30c

Abiomed (NASDAQ: ABMD) reported Q1 EPS of $0.59, $0.30 better than the analyst estimate of $0.29. Revenue for the quarter came in at $165 million versus the consensus estimate of $151.11 million.

“I am proud of Abiomed’s execution during the COVID-19 pandemic, delivering on our Q1 RED phase commitments and maintaining our focus to recover hearts and save lives. We achieved sequential improvements in revenue and patients, strengthened our clinical data, and advanced our pipeline technology,” said Michael R. Minogue, Abiomed’s Chairman, President and Chief Executive Officer. “We will make fiscal year 2021 one of the most productive and transformative years for the company as we build Abiomed 2.0 and continue to innovate products that are smaller, smarter and more connected, while we pursue studies for Class I guidelines.”

GUIDANCE:

Due to the uncertain scope and duration of the COVID-19 pandemic and the timing of global recovery, the company has not provided full year revenue or operating margin guidance. The company will continue to analyze and monitor this dynamic environment and will continue to provide transparency around results and trends. The company will reassess after each quarter and provide an update on guidance as appropriate.

For earnings history and earnings-related data on Abiomed (ABMD) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Stardust Power (SDST) Tops Q2 EPS by 1c
• RCM Technologies (RCMT) Tops Q2 EPS by 17c